NADAC acquisition cost data for HAILEY 21 1.5 MG-30 MCG TAB. This is a generic medication, typically more affordable than brand-name equivalents.
| NDC | NADAC/Unit | Effective Date | Type |
|---|---|---|---|
| 68462050479 | $0.4741 | 2022-12-21 | Rx |
| 68462050481 | $0.4741 | 2022-12-21 | Rx |
| 68462050479 | $0.4741 | 2022-12-21 | Rx |
| 68462050481 | $0.4741 | 2022-12-21 | Rx |
Generic: Norethindrone Ac-Eth Estradiol | Manufacturer: Overall
| Year | Total Spending | Claims | Beneficiaries | Cost/Unit |
|---|---|---|---|---|
| 2019 | N/A | N/A | N/A | N/A |
| 2020 | $26.8K | 706 | 215 | $0.8628 |
| 2021 | $51.9K | 1,553 | 382 | $0.8372 |
| 2022 | $62.3K | 2,082 | 517 | $0.7188 |
| 2023 | $90.7K | 2,460 | 683 | $0.8045 |
| State | Total Cost | Claims | Beneficiaries |
|---|---|---|---|
| Florida | $8.7K | 276 | 75 |
| Texas | $6.8K | 203 | 47 |
| California | $6.4K | 199 | 64 |
| Massachusetts | $4.7K | 166 | 28 |
| Washington | $4.0K | 93 | 25 |
| Michigan | $4.0K | 101 | 33 |
| Tennessee | $3.8K | 82 | 24 |
| New York | $3.4K | 116 | 28 |
| Wisconsin | $3.4K | 68 | 20 |
| North Carolina | $3.2K | 85 | 27 |
| Illinois | $2.8K | 64 | 21 |
| Arizona | $2.6K | 45 | 18 |
| Oregon | $2.4K | 62 | 17 |
| Virginia | $2.2K | 47 | 15 |
| Pennsylvania | $2.2K | 67 | 13 |
| Missouri | $2.1K | 59 | 12 |
| Colorado | $2.1K | 42 | 16 |
| Arkansas | $1.9K | 64 | 13 |
| Alabama | $1.9K | 36 | 16 |
| Georgia | $1.9K | 56 | 17 |
| New Jersey | $1.8K | 41 | N/A |
| Oklahoma | $1.7K | 29 | 12 |
| Utah | $1.5K | 50 | N/A |
| Minnesota | $1.4K | 32 | 13 |
| Ohio | $1.3K | 31 | 14 |
| Kansas | $1.2K | 49 | N/A |
| Maryland | $1.2K | 37 | N/A |
| Louisiana | $1.0K | 22 | N/A |
| Connecticut | $970.61 | 22 | N/A |
| Maine | $805.29 | 12 | N/A |
| Indiana | $774.30 | 29 | N/A |
| Idaho | $747.94 | 29 | N/A |
| South Carolina | $741.20 | 15 | N/A |
| Nebraska | $728.85 | 22 | N/A |
| Kentucky | $714.72 | 22 | N/A |
| Nevada | $452.90 | 12 | N/A |
| Mississippi | $426.06 | 18 | N/A |
The DrugPricePeek editorial team aggregates and verifies drugs data from CMS NADAC & Medicare Part D. Every statistic on this site is cross-referenced against the official source before publication, with quarterly re-verification cycles.
Read our full methodology or contact us with corrections.